The $1.4 Billion Food Is Medicine Financing Gap

A medically tailored meal provider has a signed contract with a Medicaid managed-care plan. The clinical case is settled: recipients in this category use the emergency room 70 percent less and cost the system about $220 less per member each month. The provider wants to build a production kitchen and take on more patients. The bank will not underwrite a nonprofit with no equity cushion and a contract that pays 90 to 128 days after the meal is delivered. The plan is willing to pay. The kitchen cannot get built.

That gap, between a reimbursable contract and the capital to deliver against it, is the subject of this note. Across U.S. food-is-medicine providers, it runs to about $1.4 billion over the next five years. It is a financing problem, and debt is the instrument that fits it.

What food is medicine actually is

Food is medicine covers a set of clinical interventions that treat diet-sensitive disease with food delivered through the health-care system rather than the charitable one: medically tailored meals for people managing serious illness, produce prescriptions for patients with diabetes and hypertension, and medically supportive grocery benefits. Roughly 90 percent of U.S. health-care spending goes to managing chronic disease. Diabetes alone cost $412.9 billion in 2022. About 43 million Americans are eligible for some food-is-medicine intervention, and more than 14 million meet the clinical and social criteria for medically tailored meals specifically.

The category recently crossed the threshold that matters to a lender. The evidence is peer-reviewed, the cost savings are documented, and payers are contracting for the service. A 2019 study in JAMA Internal Medicine found a 16 percent reduction in total health-care costs among meal recipients. California's CalAIM program, which began covering medically supportive food in 2022, reported inpatient use down 21 percent and emergency use down 22 percent among participants. Nine states now cover medically tailored meals through Medicaid.

Why demand is not the problem

The reflex is to treat this as an early-stage market waiting for proof. It is past that. Medicaid Section 1115 waivers and managed-care in-lieu-of-services authority let states pay for food, and they are doing it on published fee schedules. The question is no longer whether payers will reimburse. It is whether the providers, hubs, and platforms will have the capital in place to deliver against those contracts.

They mostly do not, for a structural reason. The organizations delivering this care are nonprofits and thin-margin operators. A conventional lender looks at one and sees a set of unbankable facts: no equity to cushion losses, informal governance, revenue concentrated in a single payer, and a contract that settles on a cycle running past 90 days. In 2024, the roughly 20 accredited medically tailored meal providers and their peers delivered just over four million meal-equivalents. Serving a materially larger share of the 14 million eligible requires purpose-built kitchens, and one at the scale of a leading provider costs $12 million to $20 million. These are nonprofits: they cannot issue equity, and about two-thirds of even a flagship provider's budget still comes from donations rather than payer contracts.

Where the $1.4 billion sits

The gap splits into three segments, each large enough to matter on its own.

Clinical meal providers account for about $610 million. This is the capacity to build and staff production kitchens, plus the working capital to carry a reimbursement float while a Medicaid plan settles a claim.

Aggregation and produce prescription account for about $500 million. Regional food hubs and produce-Rx platforms need cold-chain capacity and the working capital to pay farmers in 14 days while payers settle in 60 to 128. There are roughly 400 food hubs nationally, and about half report difficulty accessing capital. The produce-prescription evidence is its own: a 12-state study of 3,881 participants found measurable reductions in blood pressure and blood sugar and a one-third drop in reported food insecurity.

Tech-enabled platforms account for about $290 million. These are the for-profit companies that connect payers, providers, and patients. Venture capital has funded their growth, on the order of $400 million across the field, but equity is an expensive way to finance a government-payer receivable that turns over in months, and a conventional revolver is hard to secure against a contract rather than a hard asset.

Why grants help and why they run out

Public and philanthropic capital has moved into this field. The 2022 White House Conference on Hunger, Nutrition, and Health drew $8 billion in combined commitments. The Rockefeller Foundation has committed more than $100 million and launched a $10 million Food is Medicine Impact Fund in January 2026. This capital is necessary. It is not sufficient, for three reasons.

Grants rarely cover more than a third to a half of a capital project, so the operator still has to raise the balance. Grant timelines do not match construction or contract schedules. And grants do not finance working capital: a hub can have its cold storage paid for by a grant and still fail for lack of cash to pay farmers while a managed-care plan settles a claim over 90 days. The demand signal is real and also uneven. In 2025 the federal government rescinded its standardized nutrition-waiver framework and one flagship state pilot lost funding. That is the environment patient, flexible debt is built for: contracted demand, volatile policy.

The instrument that fits

Across all three segments the binding constraint is the form of capital, not its existence. Equity, grants, and conventional senior debt are each present in the field, and each is mismatched to the underwriting reality of a mission-driven operator. What closes these deals is flexible debt that sits alongside grants and bank loans: patient on timing, structured around a payer's settlement cycle, and willing to fill the part of the project a conventional lender will not. That piece turns a project that is conceptually financeable into one that actually closes.

This is not exotic credit work. It requires a lender that underwrites to the operating reality of the borrower: a payer settlement cycle measured in months, a nonprofit balance sheet with no equity, and a contract subject to political renewal. Price capital to that reality rather than to a generalized discount, and the interventions that already work get the capacity to reach the patients who qualify.

About the Author

Charles Wade is the founder of Fullerfield, which plans to provide flexible capital to mission-driven food and health operators. He spent 20 years structuring $8B+ in transactions at JP Morgan, Lehman Brothers, and Citigroup, and served as Investment Director at Black Farmer Fund where he deployed $6.3M across regenerative food businesses. MIT Sloan MBA, West Point graduate.

Sources & References

Figures in this note are drawn from Fullerfield Capital's 2026 research on the food-is-medicine financing gap and the public sources it reconciles to, including: Rockefeller Foundation and Dalberg Advisors food is medicine state economic analysis (2024, 2026); Tufts Food is Medicine Institute (2022 to 2025); Berkowitz et al., Health Affairs (2018); JAMA Internal Medicine (2019) on medically tailored meal cost savings; produce-prescription outcomes studies published in Circulation and the Journal of the American Heart Association (2022 to 2023); California DHCS CalAIM Community Supports data (2025); USDA Gus Schumacher Nutrition Incentive Program; MSU Center for Regional Food Systems National Food Hub Survey; American Diabetes Association, Economic Costs of Diabetes in the U.S. (2022); KFF Section 1115 waiver tracking and analysis of the 2025 budget-reconciliation law; and Nonprofit Finance Fund. Figures are illustrative and do not constitute an offer to sell securities.